Ellen has 7 years of experience guiding US and global regulatory strategy for a wide range of sponsors, products, and therapeutic areas, including oncology, rare diseases, fibrotic diseases, and infectious diseases. She has extensive experience providing support for both early and late-stage drug development programs and has particular niche expertise in orphan drugs. Ellen has worked on a wide range of product types, including both small molecules and advanced therapies. Ellen holds a Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professional Society (RAPS) and received a BS in Chemical and Biological Engineering from Colorado State University.